Hodgkin Lymphoma, version 2.2015

Richard T. Hoppe; Ranjana H. Advani; Weiyun Z. Ai; Richard F. Ambinder; Patricia Aoun; Celeste M. Bello; Cecil M. Benitez; Philip J. Bierman; Kristie A. Blum; Robert Chen; Bouthaina Dabaja; Andres Forero; Leo I. Gordon; Francisco J. Hernandez-Ilizaliturri; Ephraim P. Hochberg; Jiayi Huang; Patrick B. Johnston; Nadia Khan; David G. Maloney; Peter M. Mauch; Monika Metzger; Joseph O. Moore; David Morgan; Craig H. Moskowitz; Carolyn Mulroney; Matthew Poppe; Rachel Rabinovitch; Stuart Seropian; Christina Tsien; Jane N. Winter; Joachim Yahalom; Jennifer L. Burns; Hema Sundar

doi:10.6004/jnccn.2015.0075

Hodgkin Lymphoma, version 2.2015

Richard T. Hoppe
, Ranjana H. Advani
, Weiyun Z. Ai
, Richard F. Ambinder
, Patricia Aoun
, Celeste M. Bello
, Cecil M. Benitez
, Philip J. Bierman
, Kristie A. Blum
, Robert Chen
, Bouthaina Dabaja
, Andres Forero
, Leo I. Gordon
, Francisco J. Hernandez-Ilizaliturri
, Ephraim P. Hochberg
, Jiayi Huang
, Patrick B. Johnston
, Nadia Khan
, David G. Maloney
, Peter M. Mauch

Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Christina Tsien, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, Hema Sundar

School of Medicine

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

Original language	English (US)
Pages (from-to)	554-586
Number of pages	33
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	13
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2015.0075
State	Published - May 1 2015

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2015.0075

Cite this

Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., Benitez, C. M., Bierman, P. J., Blum, K. A., Chen, R., Dabaja, B., Forero, A., Gordon, L. I., Hernandez-Ilizaliturri, F. J., Hochberg, E. P., Huang, J., Johnston, P. B., Khan, N., Maloney, D. G., ... Sundar, H. (2015). Hodgkin Lymphoma, version 2.2015. JNCCN Journal of the National Comprehensive Cancer Network, 13(5), 554-586. https://doi.org/10.6004/jnccn.2015.0075

Hoppe, RT, Advani, RH, Ai, WZ, Ambinder, RF, Aoun, P, Bello, CM, Benitez, CM, Bierman, PJ, Blum, KA, Chen, R, Dabaja, B, Forero, A, Gordon, LI, Hernandez-Ilizaliturri, FJ, Hochberg, EP, Huang, J, Johnston, PB, Khan, N, Maloney, DG, Mauch, PM, Metzger, M, Moore, JO, Morgan, D, Moskowitz, CH, Mulroney, C, Poppe, M, Rabinovitch, R, Seropian, S, Tsien, C, Winter, JN, Yahalom, J, Burns, JL & Sundar, H 2015, 'Hodgkin Lymphoma, version 2.2015', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 5, pp. 554-586. https://doi.org/10.6004/jnccn.2015.0075

@article{692b73c01b474d3b9991f5668e31cd31,

title = "Hodgkin Lymphoma, version 2.2015",

abstract = "Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.",

author = "Hoppe, \{Richard T.\} and Advani, \{Ranjana H.\} and Ai, \{Weiyun Z.\} and Ambinder, \{Richard F.\} and Patricia Aoun and Bello, \{Celeste M.\} and Benitez, \{Cecil M.\} and Bierman, \{Philip J.\} and Blum, \{Kristie A.\} and Robert Chen and Bouthaina Dabaja and Andres Forero and Gordon, \{Leo I.\} and Hernandez-Ilizaliturri, \{Francisco J.\} and Hochberg, \{Ephraim P.\} and Jiayi Huang and Johnston, \{Patrick B.\} and Nadia Khan and Maloney, \{David G.\} and Mauch, \{Peter M.\} and Monika Metzger and Moore, \{Joseph O.\} and David Morgan and Moskowitz, \{Craig H.\} and Carolyn Mulroney and Matthew Poppe and Rachel Rabinovitch and Stuart Seropian and Christina Tsien and Winter, \{Jane N.\} and Joachim Yahalom and Burns, \{Jennifer L.\} and Hema Sundar",

note = "Publisher Copyright: {\textcopyright} JNCCN - Journal of the National Comprehensive Cancer Network.",

year = "2015",

month = may,

day = "1",

doi = "10.6004/jnccn.2015.0075",

language = "English (US)",

volume = "13",

pages = "554--586",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "5",

}

TY - JOUR

T1 - Hodgkin Lymphoma, version 2.2015

AU - Hoppe, Richard T.

AU - Advani, Ranjana H.

AU - Ai, Weiyun Z.

AU - Ambinder, Richard F.

AU - Aoun, Patricia

AU - Bello, Celeste M.

AU - Benitez, Cecil M.

AU - Bierman, Philip J.

AU - Blum, Kristie A.

AU - Chen, Robert

AU - Dabaja, Bouthaina

AU - Forero, Andres

AU - Gordon, Leo I.

AU - Hernandez-Ilizaliturri, Francisco J.

AU - Hochberg, Ephraim P.

AU - Huang, Jiayi

AU - Johnston, Patrick B.

AU - Khan, Nadia

AU - Maloney, David G.

AU - Mauch, Peter M.

AU - Metzger, Monika

AU - Moore, Joseph O.

AU - Morgan, David

AU - Moskowitz, Craig H.

AU - Mulroney, Carolyn

AU - Poppe, Matthew

AU - Rabinovitch, Rachel

AU - Seropian, Stuart

AU - Tsien, Christina

AU - Winter, Jane N.

AU - Yahalom, Joachim

AU - Burns, Jennifer L.

AU - Sundar, Hema

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

AB - Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

UR - https://www.scopus.com/pages/publications/84995810844

UR - https://www.scopus.com/pages/publications/84995810844#tab=citedBy

U2 - 10.6004/jnccn.2015.0075

DO - 10.6004/jnccn.2015.0075

M3 - Article

C2 - 25964641

AN - SCOPUS:84995810844

SN - 1540-1405

VL - 13

SP - 554

EP - 586

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Hodgkin Lymphoma, version 2.2015

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this